Despite the fact that marijuana remains illegal at the federal level, companies like HempMedsPx claim their CBD products are legal in all 50 states. According to a legal opinion written by Medical Marijuana, Inc.’s attorney and submitted to the New Republic, “HempMedsPx’s CBD hemp oil, containing naturally occurring CBD and miniscule amount of THC, is exempted from the definition of marijuana, is not a controlled substance, complies with the Controlled Substances Act, and is legal on the federal level.” The opinion is based in large part on a 2004 court ruling which allowed the importation of hemp food products derived from the mature stalks of cannabis plants.
Former President Barack Obama defined industrial hemp as a distinct crop from marijuana in the 2014 U.S. Farm Bill, authorizing higher education institutions and state agricultural departments to give the green light to "regulate and conduct research and pilot programs." But with its classification as a Schedule 1 drug still in effect, the path toward cultivating industrial hemp hasn't been an easy one.
Epidemiologic studies examining one association of Cannabis use with head and neck squamous cell carcinomas have also been inconsistent in their findings. A pooled analysis of nine case-control studies from the U.S./Latin American International Head and Neck Cancer Epidemiology (INHANCE) Consortium included information from 1,921 oropharyngeal cases, 356 tongue cases, and 7,639 controls. Compared with those who never smoked Cannabis, Cannabis smokers had an elevated risk of oropharyngeal cancers and a reduced risk of tongue cancer. These study results both reflect the inconsistent effects of cannabinoids on cancer incidence noted in previous studies and suggest that more work needs to be done to understand the potential role of human papillomavirus infection. A systematic review and meta-analysis of nine case-control studies involving 13,931 participants also concluded that there was insufficient evidence to support or refute a positive or negative association between Cannabis smoking and the incidence of head and neck cancers.
Folks. This article has nothing whatsoever to do wiht legalization of marijuana. Why do you keep commenting on legalizing pot, medical or otherwise? This article is about hemp. TOTALLY different. As an agricultural product it is very adaptable, forgiving and has a multitude of uses. Please stay on topic and help to promote the valuable product of HEMP. South Carolina has made it legal to grow and the rest of the country would benefit from following suit. Again, this has absolutely nothing to do with Pot!!!!!
Marijuana regulators in Washington State will entertain sweeping changes to how marijuana is tested, processed, packaged and sold in one of the U.S.’s oldest recreational marijuana markets, officials announced late Wednesday. Recreational cannabis has been sold in regulated retail outlets in Washington since 2014. Consumers there pay one of the country’s highest tax burdens, generating … Continue reading Washington State Prepares To Rewrite Marijuana Testing And Packaging Rules
Hemp, the non-psychoactive variety of the cannabis sativa plant, is already being integrated into several mature markets such as food, textiles, construction, personal care and nutraceuticals. This relatively quiet cannabis relative is emerging as a potential commodity ripe to not only impact, but possibly revolutionize, tech-driven markets and economies around the world.
There are thousands of unique varieties of hemp. The cultivars used for CBD oil contain significantly higher concentrations of CBD than others. Using these uniquely potent plants, it is possible to extract cannabis oil that contains significant levels of cannabidiol, as well as essential vitamins, minerals, fatty acids, terpenes, flavonoids, and other non-psychoactive cannabinoids.
Until 2017, products containing cannabidiol that are marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA) and could not be marketed without regulatory approval for the medical claims. CBD oil with THC content not exceeding 0.2% was legalized throughout the UK in 2017. Cannabis oil, however, remained illegal to possess, buy and sell.
But recent activity in Washington has legislators in every aisle waving banners for hemp. So far, 20 states have stepped up to encourage industrial hemp production.5 On February 7, 2014, the 2013 Farm Bill6 was signed into law, legitimizing industrial hemp as distinct, and authorizing university and State departments of agriculture (where it’s legal) for research or pilot programs. On January 8, 2015, The Industrial Hemp Farming Act of 2015, S. 134, was introduced in the U.S. Senate.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The public forum sessions provided an overview of the Alternative Crop Research Act, including the legal parameters set within the bill, and the procedures that will guide development of the rules and regulations. Guest speakers included Brent Burchett, the director of the plant division from the Kentucky Department of Agriculture, and Mitch Yergert, retired director of the division of plant industry from the Colorado State Department of Agriculture.
More round, soft, and green than sesame seeds and slightly sweeter than sunflower seeds, hemp seeds can be used to make hemp nut butter with a slight greenish cast from the chlorophyll. The oil has been described as having a pleasantly nutty, slightly bitter taste, and off-yellow to dark green coloring. High in unsaturated fatty acids, it can easily oxidize, so it’s not recommended for frying or baking.
With respect to fiber, a “composite” is often defined as a material consisting of 30%–70% fiber and 70%–30% matrix (Bolton 1995). However, in North America particleboards and fiberboards, which generally contain less than 10% adhesive or matrix, are sometimes referred to as composites. This section addresses plastic-type composites. In plastics, fibers are introduced to improve physical properties such as stiffness, impact resistance, bending and tensile strength. Man-made fibers of glass, kevlar and carbon are most commonly used today, but plant fibers offer considerable cost savings along with comparable strength properties.
As with a fermented food like kombucha, slight natural variations are normal and to be expected in a product such as CBD oil because it is made from living plants. Changes in the weather, soil, and water can all impact the biology of the source material. While we verify Certificates of Analysis (and take many other criteria into consideration during our review process), even the most reputable five-star companies have no way to control for every variable in this organic process.
Nabiximols (Sativex), a Cannabis extract with a 1:1 ratio of THC:CBD, is approved in Canada (under the Notice of Compliance with Conditions) for symptomatic relief of pain in advanced cancer and multiple sclerosis. Canada, New Zealand, and some countries in Europe also approve nabiximols for spasticity of multiple sclerosis, a common symptom that may include muscle stiffness, reduced mobility, and pain, and for which existing therapy is unsatisfactory.
A 2016 review of animal studies indicated that cannabidiol has potential as an anxiolytic for relief of anxiety-related disorders and fear. Reviews of preliminary research showed cannabidiol has potential for improving addictive disorders and drug dependence, although as of 2016, they indicated limited high-quality evidence for anti-addictive effects in people.
In a randomized clinical trial, researchers compared the safety and effectiveness of orally administered Cannabis extract (2.5 mg THC and 1 mg CBD), THC (2.5 mg), or placebo for the treatment of cancer-related anorexia-cachexia in 243 patients with advanced cancer who received treatment twice daily for 6 weeks. Results demonstrated that although these agents were well tolerated by these patients, no differences were observed in patient appetite or quality of life among the three groups at this dose level and duration of intervention.
CBD has also been demonstrated to exert a chemopreventive effect in a mouse model of colon cancer. In this experimental system, azoxymethane increased premalignant and malignant lesions in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In in vitro experiments involving colorectal cancer cell lines, the investigators found that CBD protected DNA from oxidative damage, increased endocannabinoid levels, and reduced cell proliferation. In a subsequent study, the investigators found that the antiproliferative effect of CBD was counteracted by selective CB1 but not CB2 receptor antagonists, suggesting an involvement of CB1 receptors.
One systematic review studied 30 randomized comparisons of delta-9-THC preparations with placebo or other antiemetics from which data on efficacy and harm were available. Oral nabilone, oral dronabinol, and intramuscular levonantradol (a synthetic analog of dronabinol) were tested. Inhaled Cannabis trials were not included. Among all 1,366 patients included in the review, cannabinoids were found to be more effective than the conventional antiemetics prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, and alizapride. Cannabinoids, however, were not more effective for patients receiving very low or very high emetogenic chemotherapy. Side effects included a feeling of being high, euphoria, sedation or drowsiness, dizziness, dysphoria or depression, hallucinations, paranoia, and hypotension.
You cannot have a fatal overdose from cannabis use. However, if you have too much in one session it can lead to a very unpleasant experience. Anxiety and panic attacks, disorientation, and inability to focus are all signs you have had too much. Other negative effects from taking too much include loss of coordination, shortness of breath, increased heart rate and shaking, chills and sweats.
Jump up ^ Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M (January 2008). "Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism". Brain Research. 1188: 157–64. doi:10.1016/j.brainres.2007.09.090. PMID 18021759.
Cannabis is used in three main forms: marijuana, hashish and hash oil. Marijuana is made from dried flowers and leaves of the cannabis plant. It is the least potent of all the cannabis products and is usually smoked or made into edible products like cookies or brownies (see Factsheet: Marijuana Edibles). Hashish is made from the resin (a secreted gum) of the cannabis plant. It is dried and pressed into small blocks and smoked. It can also be added to food and eaten. Hash oil, the most potent cannabis product, is a thick oil obtained from hashish. It is also smoked.
Ten trials have evaluated the efficacy of inhaled Cannabis in chemotherapy-induced N/V.[35-38] In two of the studies, inhaled Cannabis was made available only after dronabinol failure. In the first trial, no antiemetic effect was achieved with marijuana in patients receiving cyclophosphamide or doxorubicin, but in the second trial, a statistically significant superior antiemetic effect of inhaled Cannabis versus placebo was found among patients receiving high-dose methotrexate. The third trial was a randomized, double-blind, placebo-controlled, crossover trial involving 20 adults in which both inhaled marijuana and oral THC were evaluated. One-quarter of the patients reported a favorable antiemetic response to the cannabinoid therapies. This latter study was reported in abstract form in 1984. A full report, detailing the methods and outcomes apparently has not been published, which limits a thorough interpretation of the significance of these findings.
From 1982 to 2002 the EU provided the equivalent of about 50 million dollars to develop new flax and hemp harvesting and fiber processing technologies (Karus et al. 2000). Because of the similarities of flax and hemp, the technologies developed for one usually are adaptable to the other. In addition, various European nations and private firms contributed to the development of hemp technologies. Accordingly, Europe is far more advanced in hemp development with respect to all fiber-based applications than other parts of the world. The EU currently dedicates about 30,000 ha to hemp production. France is the leading country in hemp cultivation in the EU, and 95% of the non-seed production is used for “specialty pulp” as described below. Harvesting and processing machinery for fiber hemp is highly advanced in Europe, and some has been imported into Canada. However, there is insufficient fiber processing capacity to handle hemp produced in Canada.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Users have reported toxic symptoms, extreme reactions and serious psychological problems from using synthetic cannabis. These include: high blood, pressure, abdominal pain, nausea and vomiting, chest pain, heart palpitations, severe anxiety and paranoia, fear of dying, hallucinations, tremors and seizures, violent behaviour, and suicidal thoughts. These toxic symptoms have lasting several days and others have experienced long term mental health issues. Tolerance can develop quickly which means you will need more to get the same effect.